
Regeneron appoints senior VP from Pfizer
pharmafile | September 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Pfizer, Regeneron, landry
Regeneron Pharmaceuticals has hired Robert Landry from Pfizer to be its senior vice president and chief financial officer.
Landry will assume the positions in the biopharma firm from 1 October, and after 18 years spent as the firm’s previous CFO, Murray Goldberg will transition to a new role as senior VP, Administration in anticipation of his retirement at the end of 2014.
Landry brings over two decades of varied financial and operating experience in the global pharma industry, most recently as senior VP and treasurer of Pfizer. He will report to Leonard Schleifer, president and chief executive of Regeneron.
Schleifer said: “Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth. We look forward to the valuable perspective he will bring, as we continue to expand our operations in the US and globally.”
Landry added: “I am pleased to be able to join an organisation that is known for its deep commitment to science and to bringing life changing medicines to patients. I am excited about this opportunity and look forward to working with the talented Regeneron management team.”
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …






